Europe
Although bioterrorism doesn’t get the kind of attention more traditional bombings and shootings receive, the biotech industry and the federal government are paying attention and actively funding and developing countermeasures to potential bioterror, military and public health emergencies.
Over the next two weeks, the U.S. Food and Drug Administration (FDA) has three upcoming decisions. Here’s a look.
Sidley Austin LLP is pleased to announce that former European Medicines Agency Senior Legal Adviser Georgia Gavriilidou has joined the firm as counsel in its London office.
This novel microfluidic droplet sorter will be deployed downstream of the MemoMAB antibody repertoire biobanking platform to enable functional screening in high througput format with a series of functional assays
Auris Medical Holding AG announced the complete repayment of its loan facility with Hercules Capital, Inc.
Promore Pharma AB announced that the company is making adjustments to the manufacturing chain of the investigational medicinal product for the company’s clinical phase III study, PSHU03, with PXL01 for prevention of adhesions following tendon repair surgery.
Data complements previously published results showing activity of NOX-E36 in pancreatic cancer
Immunicum AB announced that Carlos de Sousa, CEO of Immunicum, and other members of the management team will present at upcoming investor conferences in February.
Four months after getting the green light in the U.K. for treatment of children with acute lymphoblastic leukemia (ALL), Novartis’ CAR-T treatment Kymriah, known as Tisagenlecleucel in the U.K., has gained approval for treatment of adults with diffuse large B-cell lymphoma (DLBCL).
MorphoSys AG announced today that in its lawsuit against Janssen Biotech and Genmab A/S, the parties have settled the dispute.
PRESS RELEASES